Biomark Diagnostics Inc. (CSE: BUX)

Market Cap	17.18M
Revenue (ttm)	158.01K
Net Income (ttm)	-1.97M
Shares Out	n/a
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,000
Open	0.220
Previous Close	0.225
Day's Range	0.220 - 0.220
52-Week Range	0.180 - 0.315
Beta	-0.54
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 22, 2024

About Biomark Diagnostics

Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic platform to detect, monitor, and treat cancer. The company invests in and develops liquid biopsy metabolic panel assay for early stage diagnosis of lung cancer. It has a strategic partnership with Rubix LS to develop diagnostic tools to enhance lung cancer screening and improve breast cancer screening program for women with dense breasts. The company was incorporated in 2014 and is headquartered in Richmond, Canada.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2014
• Country: Canada
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: BUX

Financial Performance

In 2023, Biomark Diagnostics's revenue was 163,220, an increase of 6.34% compared to the previous year's 153,492. Losses were -1.43 million, -22.52% less than in 2022.